Showing 821-830 of 1211 results for "".
- Registration Now Open for Neuro-Optometric Rehabilitation Association Meetinghttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-meeting/2476291/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) Clinical Skills Pre-Conference (September 19-20) and 28th annual General Conference (September 21-22) at the Embassy Suites by Hilton Scottsdale Resorts, Scottsdale, Arizona. The
- MPOD Measurement Earns American Medical Association CPT III Codehttps://modernod.com/news/mpod-measurement-earns-american-medical-association-cpt-iii-code/2480039/EyePromise announced that on July 1, 2018, macular pigment optical density (MPOD) measurement by heterochromatic flicker photometry has earned a Category III CPT Code from the American Medical Association. While this code does not receive paid reimbursement, Category III CPT Codes are used for da
- Study: AMD Strongly Associated With Heart Disease and Strokehttps://modernod.com/news/study-blinding-eye-disease-is-strongly-associated-with-heart-disease-and-stroke/2480958/Patients with a specific form of age-related macular degeneration (AMD) are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai. This study, published in the July issue of Retina, is the first t
- Retina Consultants of America Adds Colorado Retina Associateshttps://modernod.com/news/retina-consultants-of-america-adds-colorado-retina-associates/2480368/
- Bausch + Lomb Receives CPT Category 1 Code for Xipere from the American Medical Associationhttps://modernod.com/news/bausch-lomb-receives-cpt-category-1-code-for-xipere-from-the-american-medical-association/2481954/Bausch + Lomb announced that the American Medical Association (AMA) has confirmed assignment of the Category 1 Current Procedural Terminology (CPT) code for
- Grants Available for Students, Residents to Attend Neuro-Optometric Rehabilitation Association 2023 Conferencehttps://modernod.com/news/grants-available-for-students-residents-to-attend-neuro-optometric-rehabilitation-association-2023-conference-2023-conferenc/2481463/The Neuro-Optometric Rehabilitation Association International (NORA) is offering up to 10 students and residents with an interest in neuro-rehabilitation an opportunity to apply for a student grant (
- International Sports Vision Association and Macuhealth Offer New Educational Resource on Sports Nutrition for Your Eyeshttps://modernod.com/news/international-sports-vision-association-and-macuhealth-offer-new-educational-resource-on-sports-nutrition-for-your-eyes/2479270/The International Sports Vision Association (ISVA) and MacuHealth announced the launch of “Sports Nutrition for Your Eyes,” a new educational resource on the ISVA website designed to help educate athletes about how proper nutrition ca
- Clearside Biomedical Announces Resubmission of NDA for Xipere for Treatment of Macular Edema Associated with Uveitishttps://modernod.com/news/clearside-biomedical-announces-resubmission-of-nda-for-xipere-for-treatment-of-macular-edema-associated-with-uveitis/2479154/Clearside Biomedical announced the resubmission of its new drug application (NDA) to the FDA for Xipere (triamcinolone acetonide suprachoroidal injectable suspension) for the treatment of macular edema associated with uveitis. Clearside’s resubmission is a f
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2478693/Ocular Therapeutix announced the submission of the supplemental new drug application (sNDA) to the FDA for Dextenza (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use. If approved, this sNDA would include the treatment of ocular itching associated with allergic conjunctivitis as an
- AstraZeneca to Study BTK Inhibitor Calquence as Treatment for Cytokine Storm Associated With COVID-19 Infectionhttps://modernod.com/news/astrazeneca-to-study-btk-inhibitor-calquence-as-treatment-for-cytokine-storm-associated-with-covid-19-infection/2477575/AstraZeneca announced that it will investigate the potential of the BTK inhibitor Calquence (acalabrutinib) in the treatment of the cytokine storm associated with COVID-19 infection in severely ill patients. The company noted that the design of the CALAVI study is based on “strong scientifi